Contract sales provider PDI said Sanofi-Aventis would end its $20 million sales agreement with the firm, effective Dec. 1.
The deal was set to expire Dec. 31, PDI said.
The end of the firm’s Sanofi-Aventis deal comes a month after GlaxoSmithKline
decided not to renew a $65 million to $70 million contract with PDI for 2007. In April, AstraZeneca also ended a $65 million to $70 million agreement with PDI, affecting approximately 800 field representatives.
PDI “has been significantly impacted” as the world’s top pharma companies re-evaluate their commercial models, CEO Michael Marquad said in a statement.
“The decisions our customers have made have been based upon this reassessment and not related to the performance of our sales teams.”